Know Cancer

or
forgot password

Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer


N/A
18 Years
N/A
Open (Enrolling)
Both
Bone Cancer

Thank you

Trial Information

Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer


The objective of the study is to use 18F sodium fluoride (fluorine F-18 sodium fluoride)
PET/CT scanning to detect and characterize lesions in patients who have suspected skeletal
malignancy. We hypothesize that scanning with 18F-NaF (fluorine F-18 sodium fluoride) is
more sensitive for skeletal abnormalities and may better characterize lesions than
conventional imaging.


Inclusion Criteria:



- Patients referred for evaluation of suspected skeletal cancer

- Patients must understand and voluntarily sign an informed consent form after the
contents have been fully explained to them

Exclusion Criteria:

- Patients who cannot complete a PET/CT scan

- Pregnant women

- Healthy volunteers

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Number of lesions with fluorine F 18 sodium fluoride PET/CT in patients who have suspected skeletal malignancy

Outcome Description:

Imaging will take approximately two hours in total.

Outcome Time Frame:

2 hours

Safety Issue:

No

Principal Investigator

Andrew Quon

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Food and Drug Administration

Study ID:

VAR0074

NCT ID:

NCT01541358

Start Date:

May 2012

Completion Date:

Related Keywords:

  • Bone Cancer
  • Bone Neoplasms
  • Osteosarcoma

Name

Location

Stanford UniversityStanford, California  94305